Cingulate (CINGW) Net Income towards Common Stockholders (2021 - 2026)
Cingulate's (CINGW) quarterly Net Income towards Common Stockholders came in at -$5.9 million in Q2 2026, down 17.8% on a YoY basis from -$7.1 million in Q2 2025, and down 18.49% quarter-over-quarter from -$5.0 million in Q4 2025.
Powered by 
Analysis
Cingulate (CINGW) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$5.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 17.8% year-over-year to -$5.9 million; the trailing twelve-month figure through Jun 2026 stood at -$21.6 million (down 33.63% YoY), and the FY2025 full-year result was -$17.7 million, down 35.57% from the prior year.
- Net Income towards Common Stockholders slipped to -$5.9 million in Q2 2026 per CINGW's latest filing, from -$5.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$2.4 million in Q1 2024 and bottomed at -$5.9 million in Q2 2026.
- Historically, Net Income towards Common Stockholders has averaged -$4.1 million across 5 years, with a median of -$4.0 million in 2022.
- The widest YoY moves for Net Income towards Common Stockholders: up 79.19% in 2022, down 197.16% in 2022.
- Over 5 years, Net Income towards Common Stockholders stood at -$3.6 million in 2022, then tumbled by 51.22% to -$5.5 million in 2023, then grew by 10.24% to -$4.9 million in 2024, then slipped by 0.64% to -$5.0 million in 2025, then decreased by 18.49% to -$5.9 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$5.9 million, -$5.0 million, and -$5.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.03 Bn | 625.27 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 441.99 Bn | 435.42 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 366.30 Bn | 359.16 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn | 3.26 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | -238.00 Mn |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | 398.69 Mn |
| 7 | Revolution Medicines | 44.13 Bn | 44.13 Bn | - | -644.37 Mn |
| 8 | Incyte | 25.53 Bn | 20.99 Bn | 1.57 Bn | 585.61 Mn |
| 9 | United Therapeutics | 21.51 Bn | 18.85 Bn | 683.80 Mn | 333.00 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | -5.87 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.87 Mn |
| Dec 31, 2025 | -4.95 Mn |
| Sep 30, 2025 | -5.80 Mn |
| Jun 30, 2025 | -4.98 Mn |
| Mar 31, 2025 | -3.00 Mn |
| Dec 31, 2024 | -4.92 Mn |
| Sep 30, 2024 | -3.26 Mn |
| Jun 30, 2024 | -2.50 Mn |
| Mar 31, 2024 | -2.38 Mn |
| Dec 31, 2023 | -5.48 Mn |
| Sep 30, 2023 | -4.72 Mn |
| Jun 30, 2023 | -5.23 Mn |
| Mar 31, 2023 | -3.16 Mn |
| Dec 31, 2022 | -3.63 Mn |
| Sep 30, 2022 | -3.18 Mn |
| Jun 30, 2022 | -3.19 Mn |
| Mar 31, 2022 | -3.96 Mn |
| Dec 31, 2021 | -2.65 Mn |
| Sep 30, 2021 | -15.29 Mn |
| Jun 30, 2021 | -1.43 Mn |